GFRAL (JMT-203 Biosimilar) Recombinant Monoclonal Antibody

This recombinant monoclonal antibody is developed as a research-grade biosimilar to JMT-203, targeting GFRAL (GDNF family receptor alpha-like), a recently identified receptor that plays a critical role in energy homeostasis and metabolic regulation. GFRAL is predominantly expressed in the hindbrain area postrema and functions as the receptor for GDF15 (growth differentiation factor 15), mediating anorexia, weight loss, and metabolic stress responses. The GFRAL-GDF15 signaling axis has emerged as a significant therapeutic target in obesity, cachexia, cancer-associated anorexia, and metabolic disorders, as elevated GDF15 levels are associated with various pathological conditions including cancer, cardiovascular disease, and metabolic syndrome.

JMT-203 represents a valuable research tool for investigating GFRAL-mediated signaling pathways and their physiological consequences. This biosimilar antibody enables researchers to explore the mechanisms underlying GDF15-GFRAL interactions, study metabolic regulation in preclinical models, and evaluate potential therapeutic interventions targeting this pathway. It serves as an essential reagent for advancing understanding of energy balance, appetite regulation, and stress-induced metabolic responses in both normal physiology and disease states.